p38 MAP kinase inhibitors (Merckle)

N/A

Report date: 2025/06/11 20:01:15
NME

Base Information

Drug Namep38 MAP kinase inhibitors (Merckle)
Drug Alias Namecytokine release inhibitors (Merckle)ML-3163ML-3375ML-3403
ClassificationSmall molecules
Mechanisms of ActionP38 α mitogen-activated protein kinase inhibitorsTNF alpha synthesis inhibitorsCytokine release inhibitors +[4] 
TargetsInterleukin-1 betaP38 α mitogen-activated protein kinase
Therapy Area/IndicationsInflammationInflammatory Bowel DiseasesArthritis, Rheumatoid
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryGermany
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesMerckle Gmbh
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesC-A-I-R BiosciencesMerckle Gmbh
Active IndicationsN/A
Inactive IndicationsInflammationInflammatory Bowel DiseasesArthritis, Rheumatoid

Other Information

ATC CodeN/A
Related LinksN/A